MUNDIPHARMA
24.4.2024 22:02:28 CEST | Business Wire | Press release
Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics.
This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafungin is a novel once-weekly echinocandin indicated for the treatment of invasive candidiasis in adults.1
Invasive candidiasis, is a severe, life-threatening infection of the bloodstream and/or deep/visceral tissues.2,3 It affects seriously ill people, especially those with a weakened immune system and the mortality rate can be 40%4 or more.5,6 It can place a large burden on the healthcare system, with the potential for extended treatment regimens and long hospital stays.6 Over the last 15 years, there have been no new treatments and morbidity and mortality rates remain largely the same, indicating the need for alternative treatment options.7,8
“This acquisition places Mundipharma in the best position to realise the full potential of rezafungin including its availability and ongoing development. We are committed to ensuring patients affected with invasive candidiasis have access to an additional treatment option to manage this potentially life-threatening condition,” said Marc Princen, Chief Executive Officer at Mundipharma.
Rezafungin received approval by the U.S. Food and Drug Administration (FDA) in March 20239 and the European Commission (EC) in December 202310. It has also been authorised for use by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in January 202411 and the UAE Ministry of Health and Prevention (MOHAP) in March 2024. Rezafungin has been granted Orphan Drug Designation for the treatment of invasive candidiasis in the US12, EU13 and UK.14 It is currently available to patients in the UK and Germany, and further marketing authorisation applications are subject to accelerated review procedures to support getting this important medicine to patients.
Commercialisation rights to rezafungin in the United States will remain licensed to Melinta Therapeutics.
*Assets and rights acquired by Napp Pharmaceutical Group Limited, a member of the international network of Mundipharma independent associated companies.
*ENDS*
About invasive candidiasis
Invasive candidiasis (IC) continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems. Despite a number of available treatments, the mortality rate for patients with invasive candidiasis is 40%4 or more.5,6 IC is characterised as a severe, life-threatening systemic Candida infection of the bloodstream and/or deep/visceral tissues, known as candidemia and deep-seated tissue candidiasis.15
About Mundipharma
Mundipharma is a global healthcare company focussing on customers across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East.
Mundipharma is dedicated to bringing innovative treatments to patients in the areas of pain management, infectious disease as well as other severe and debilitating disease areas. Their guiding principles, centred around Integrity and Patient-Centricity, are at the heart of everything they do. For more information visit www.mundipharma.com.
References:
- REZZAYO® Product Information. EPAR Medicine Overview available at: https://www.ema.europa.eu/en/medicines/human/EPAR/rezzayo (last accessed April 2024).
- Pappas PG, et al. Nat Rev Dis Primers 2018 ;4 :18026.
- CDC. Invasive candidiasis. Available at: https://www.cdc.gov/fungal/diseases/candidiasis/invasive/definition.html (last accessed April 2024).
- Kullberg BJ, Arendrup MC. N Engl J Med 2015;373:1445–56.
- Bassetti M, et al. Crit Care 2019;23(1):219.
- Cortegiani A, et al. Cochrane Database Syst Rev 2016;2016:Cd004920.
- Bassetti M, et al. J Antimicrob Chemother 2018; 73 Suppl 1: i14–i25 doi:10.1093/jac/dkx445.
- Ham YY, et al. Future Microbiology 2021;16(1):27–36.
- US Food and Drug Administration approval. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217417Orig1s000Approv.pdf (last accessed April 2024)
- European Medicines Agency approval. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/rezzayo#ema-inpage-item-assessment-history (last accessed April 2024).
- UK Medicines and Healthcare Products Regulatory Agency authorisation. Available at: https://www.gov.uk/government/news/rezzayo-approved-to-treat-adult-patients-with-invasive-candidiasis (last accessed April 2024).
- US Food and Drug Administration. Orphan drug designation notice. Available at: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=507215 (last accessed April 2024)
- European Commission. Orphan maintenance assesment report. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/rezzayo (last accessed April 2024).
- UK MHRA. Register of orphan medicinal products. Available at: https://www.gov.uk/government/publications/orphan-registered-medicinal-products/orphan-register#rezzayo (last accessed April 2024).
- Cortes JA, Corrales IF. Invasive candidiasis: Epidemiology and Risk Factors. November 2018. Available at https://www.intechopen.com/chapters/64365 (last accessed April 2024).
Job reference: SciA-RZF-2400003
Date of preparation: April 2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424542362/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press release
Canada becomes the 25th Allied nation to back the NATO Innovation Fund, gaining access to €1.1 billion in mission-aligned capital and a co-investor network spanning the Alliance Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the amb
Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press release
Independent evaluation of Persona's Android SDK confirms defenses against deepfakes and other injected media at the top level of the first standard Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release
Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
